Boehringer Ingelheim

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Retrieved on: 
Thursday, September 9, 2021
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twists proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twists proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.
  • Twist and Boehringer Ingelheim will work together to validate and optimize any resulting new antibody candidates, which could be researched against a range of therapeutic areas.
  • Boehringer Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration.
  • This discovery collaboration with Boehringer Ingelheim covering numerous targets truly illustrates the power of our antibody libraries.

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction

Retrieved on: 
Thursday, September 9, 2021

Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

Key Points: 
  • Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.
  • Allergic (hypersensitivity) reactions.Symptomsofseriousallergicreactionsto JARDIANCE mayinclude:
    If you have anyof these symptoms,stoptakingJARDIANCEandcontactyourhealthcare providerorgo to the nearestemergencyroomrightaway.
  • Before taking JARDIANCE, tellyourhealthcare providerabout all of your medical conditions, including ifyou:
    are going to have surgery.
  • Clinical trials have been initiated to evaluate the impact of Jardiance on people living with heart failure or chronic kidney disease.

Zealand Pharma Presents Data at 2021 ESPEN Virtual Congress Demonstrating Dose-dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models – in Contrast to Short-acting GLP-2

Retrieved on: 
Thursday, September 9, 2021

The Companys research presented at ESPEN 2021 will feature multiple posters, including one Poster of Distinction, related to glepaglutide for the treatment of short bowel syndrome (SBS).

Key Points: 
  • The Companys research presented at ESPEN 2021 will feature multiple posters, including one Poster of Distinction, related to glepaglutide for the treatment of short bowel syndrome (SBS).
  • The data presented at ESPEN demonstrate the attractive profile of glepaglutide following once-weekly dosing in humans and the dose-dependent effects on both small and large intestines in animals, underscoring its differentiation as a potential treatment option for SBS.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

PM Group Delivers Strong Operational and Financial Performance and Announces Creation of 400 New Jobs

Retrieved on: 
Thursday, September 9, 2021

This performance was achieved on the back of strong underlying fee income which was 9% up on prior year.

Key Points: 
  • This performance was achieved on the back of strong underlying fee income which was 9% up on prior year.
  • The Group is employee owned with over 1,000 people holding shares in the Group, up 15% on prior year.
  • PM Group is creating 400 new jobs this year across a range of disciplines including architecture, engineering, construction, data analytics, project controls and Environmental.
  • In April, the Group appointed a new Chief Financial Officer, Rosita Fennell in succession to Larry Westman.

PM Group Delivers Strong Operational and Financial Performance and Announces Creation of 400 New Jobs

Retrieved on: 
Thursday, September 9, 2021

This performance was achieved on the back of strong underlying fee income which was 9% up on prior year.

Key Points: 
  • This performance was achieved on the back of strong underlying fee income which was 9% up on prior year.
  • The Group is employee owned with over 1,000 people holding shares in the Group, up 15% on prior year.
  • PM Group is creating 400 new jobs this year across a range of disciplines including architecture, engineering, construction, data analytics, project controls and Environmental.
  • In April, the Group appointed a new Chief Financial Officer, Rosita Fennell in succession to Larry Westman.

CDR-Life Announces the Advancement of Antibody Treatment for Patients with Geographic Atrophy with Development Partner Boehringer Ingelheim

Retrieved on: 
Wednesday, September 8, 2021

ZRICH, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc ., today announced that Boehringer Ingelheim has selected an antibody fragment-based therapeutic candidate for advancement to the next phase of development under the existing agreement between the companies for the discovery and development of novel therapies for the treatment of geographic atrophy (GA), triggering an undisclosed milestone payment from Boehringer Ingelheim to CDR-Life.

Key Points: 
  • ZRICH, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- CDR-Life Inc ., today announced that Boehringer Ingelheim has selected an antibody fragment-based therapeutic candidate for advancement to the next phase of development under the existing agreement between the companies for the discovery and development of novel therapies for the treatment of geographic atrophy (GA), triggering an undisclosed milestone payment from Boehringer Ingelheim to CDR-Life.
  • GA is a blinding retinal disease that occurs in patients with age-related macular degeneration (AMD) and for which there is no treatment.
  • Boehringer Ingelheim and CDR-Life entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics forgeographic atrophyin May 2020.
  • CDR-Life is led by former biologics inventors, pharmaceutical drug developers and company builders, and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat geographic atrophy.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Retrieved on: 
Tuesday, September 7, 2021

Copenhagen, DK and Boston, MA, U.S., September 7, 2021 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S., September 7, 2021 Zealand Pharma A/S (Zealand) (Nasdaq: ZEAL), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • The above information contains forward-looking statements that provide Zealand Pharmas expectations or forecasts of future events.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Opportunities in the Global Contract Pharmaceutical Manufacturing, Research and Packaging Markets 2021-2026: A $214.7 Billion Market by 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 7, 2021
Health, Pharmaceutical

The "Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global market for contract pharmaceutical manufacturing, research and packaging services is forecast to grow from $168 billion in 2021 to $214.7 billion by 2026, at a compound annual growth rate (CAGR) of 5.0% during the forecast period of 2021-2026.
  • The global market for contract pharmaceutical manufacturing services should grow from $89.7 billion in 2021 to $110.8 billion by 2026, at a CAGR of 4.8% during the forecast period of 2021-2026.
  • The global market for contract pharmaceutical research services should grow from $67.1 billion in 2021 to $89.8 billion by 2026, at a CAGR of 6.0% during the forecast period of 2021-2026.

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

Retrieved on: 
Tuesday, September 7, 2021

NANTES, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announced today that it has received notice of allowance from the United States Patent and Trademark Office for a patent application related to Tedopi®, a combination of neoepitopes, protecting its administration schedule for inducing early T-lymphocyte memory response, used in the treatment of non-small cell lung cancer (NSCLC) in HLA-A2 positive patients. This patent will provide a protection until 2035.

Key Points: 
  • Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, said: This new patent notice of allowance granted in the U.S. further expands the patent protection for Tedopi and confirms a specific mechanism of action inducing an early T-lymphocyte memory response in HLA-A2 positive patients, which represent 45% of the population.
  • Such combinations will further reinforce the therapeutic value of Tedopi in late stage cancer indications.
  • The Tedopi treatment is compared to docetaxel or pemetrexed chemotherapy (CT) treatments, with overall survival as the primary endpoint.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Zealand Pharma to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

Retrieved on: 
Friday, September 3, 2021
Patient, DK, Diabetes, Hypoglycemia, Morgan, Morgan Stanley, AstraZeneca, Nasdaq, Conference, Zealand Pharma, Company, Adult, Webcast, Boehringer Ingelheim, Pharmaceutical industry, Online shopping

Copenhagen, DK and Boston, MA, U.S. September 3, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S. September 3, 2021 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • A replay of the webcast will be archived on the Company's website following the presentation.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines.
  • Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA).